在阿尔茨海默病中重新构建TDP-43:从共同病理到神经血管罪祸首
Martina Gaia Di Donna1, Caterina Motta1, Chiara Giuseppina Bonomi1
1Memory Clinic and Neurodegenerative Dementia Research Unit, Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 16, 2025
概括
交换性反应 (TAR) DNA 结合蛋白 43 kDa (TDP-43) 在脑细胞中聚集,在阿尔茨海默病 (AD) 中驱动神经血管单元 (NVU) 功能障碍. 这种血管-质机制突出了TDP-43作为上游驱动器,影响了血脑屏障的完整性和清除.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 涉及超出粉样β和蛋白的复杂神经血管和质功能障碍.
- 交换性反应 (TAR) DNA 结合蛋白 43 kDa (TDP-43) 病理在阿尔茨海默病中越来越被认可,传统上是神经元共同病理.
研究的目的:
- 提出一个概念框架,将TDP-43与AD中的神经血管单元 (NVU) 干扰联系起来.
- 将TDP-43从共同病理重新归类为AD进展的潜在上游驱动因素.
主要方法:
- 综合最近关于TDP-43聚合在星球细胞和内皮细胞中的证据.
- 分析TDP-43对血脑屏障 (BBB) 完整性,淋巴清除和代谢平衡的影响.
- 对血管-质机制的检查,包括β-catenin信号传递,水-4 (AQP4) 和CD146.4的检查.
主要成果:
- 内皮细胞中的TDP-43聚合物损害了BBB完整性和代谢平衡.
- 内皮TDP-43的损失破坏了β-catenin的信号传输,导致血管衰竭和神经炎症.
- 天体细胞TDP-43聚合物与减少的AQP4和CD146相关,损害了清除途径.
结论:
- 在AD中,TDP-43充当NVU功能障碍的驱动因素,影响内皮细胞和质细胞.
- 结合TDP-43的血管质模型为AD生物标志物和治疗提供了新的途径.
- 将TDP-43重新归类为上游贡献者支持针对NVU功能障碍的AD精准医学方法.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


